Overall, though -- it remains a viable combo, in certain kidney and uterine cancers.
Here's the latest, in any event -- from Reuters:
. . .[Both companies said on] Friday a combination of their cancer therapies did not prolong the lives of patients in two late-stage studies testing it as a treatment for a type of lung cancer.
The pairing of Merck's blockbuster immunotherapy Keytruda and Eisai's Lenvima has previously failed in studies evaluating it in patients with types of head-and-neck cancer, skin cancer and colon cancer as well. . . .
Now you know, but Keytruda is -- and will remain -- the most profitable drug in Merck's storied 100 plus year history. And to be clear -- Merck is, and will remain -- for decades to come. . . one of the most profitable multinationals on the planet.
So it is a little rich, that Merck refuses to discuss pricing with large customers on very mature, very overpriced diabetes medications like. . . Januvia. Ugh. But you've heard that tune, from me -- a few times before. Onward, and. . . go Buffs. . . beat the Ducks!
नमस्ते
1 comment:
Once at 7:23 pm… smiling fondly at you…
Post a Comment